Mind the Gap: A Sequential 4-Step Missing Data Management for CGM-Derived Endpoints in Diabetes Clinical Trials

Abstract

Keywords

continuous glucose monitoring data epoch level multi-layered structure data quality traceability missing data

Get full access to this article

View all access options for this article.

References

Kim

Crackel

Cho

Wang

Beyond time in range: hidden statistical challenges of continuous glucose monitoring data in diabetes drug development. J Diabetes Sci Technol. 2026;20(1):229-230.

Food and Drug Administration. Submitting continuous glucose monitoring data in clinical trials. Guidance for industry, technical specifications document. 2026. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/submitting-continuous-glucose-monitoring-data-clinical-trials

Food and Drug Administration. Digital health technologies for remote data acquisition in clinical investigations guidance for industry, investigators, and other stakeholders. 2023. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/digital-health-technologies-remote-data-acquisition-clinical-investigations

Kok

Walter

Lee

Gaynanova

Impact of missing data and monitoring duration on downstream analyses in continuous glucose monitoring. Diabetes Care. 2026;49:1031-1039.

Zhan

Fisher

Zhang

XD.

Occurrence and impact of missing data on CGM metrics-analysis of data from Type 1 Diabetes Exercise Initiative (T1DEXI). Diabetes. 2025;74(suppl 1):233-OR.

Wang

Kim

, et al. Statistical methods for handling missing data to align with treatment policy strategy. Pharm Stat. 2023;22(4):650-670.